Evidence map›Paper›PMID 36839704›Full record

ArticlePharmaceutics2023

Synthesis and Anti-Angiogenic Activity of Novel c(RGDyK) Peptide-Based JH-VII-139-1 Conjugates.

George Leonidis, Anastasia Koukiali, Ioanna Sigala, Katerina Tsimaratou, Dimitris Beis, Thomas Giannakouros, Eleni Nikolakaki, Vasiliki Sarli

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

George LeonidisDepartment of Chemistry, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece.ORCID 0000-0002-3286-4781
Anastasia KoukialiDepartment of Chemistry, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece.ORCID 0000-0002-5058-8442
Ioanna SigalaDepartment of Chemistry, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece.ORCID 0000-0002-8604-9870
Katerina TsimaratouZebrafish Disease Model Laboratory, Biomedical Research Foundation Academy of Athens, 11527 Athens, Greece.
Dimitris BeisZebrafish Disease Model Laboratory, Biomedical Research Foundation Academy of Athens, 11527 Athens, Greece.ORCID 0000-0003-2579-7848
Thomas GiannakourosDepartment of Chemistry, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece.ORCID 0000-0001-7347-407X
Eleni NikolakakiDepartment of Chemistry, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece.ORCID 0000-0003-3388-3850
Vasiliki SarliDepartment of Chemistry, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece.ORCID 0000-0002-6128-8277
Aristotle University of Thessaloniki · GRAcademy of Athens · GR

Funding

Hellenic Foundation for Research and Innovation 12
6 · The paper itself

Abstract

Peptide-drug conjugates are delivery systems for selective delivery of cytotoxic agents to target cancer cells. In this work, the optimized synthesis of JH-VII-139-1 and its c(RGDyK) peptide conjugates is presented. The low nanomolar SRPK1 inhibitor, JH-VII-139-1, which is an analogue of Alectinib, was linked to the α

Indexed as

angiogenesiscancerhybrid moleculesintegrinsPDCspeptide drug conjugatesreceptor-mediated endocytosisRGD peptideSRPK1

Identifiers

PMID36839704
PMCPMC9962512
OpenAlexW4317733588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.